JPRN-UMIN000005792已完成未知
Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial. - Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer.
Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences0 个研究点目标入组 30 人开始时间: 2011年6月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. patient who has drug allergy as past history 2. case of administration contraindication 3. patient who needs flucytosine, phenytoin, and Warfarin 4. patient who has active infectious disease with fever over 38 degree 5. patient who has severe complication (intestinal palsy, ileus, interstitial pneumonia, DM, renal failure, liver failure under bad control) 6. patient who has heart disease(CHF, old MI, IHD, arrhythmia, and a valvular disease of the heart) 7. patient who has metastatic brain tumor with symptoms 8. watery diarrhea 9. severe ascites and/or pleural effusion 10. patient who has active double cancer 11. patient who want to be pregnant and /or pregnant woman 12. man who want to have a child 13. patient who was not judged to be suitable for this clinical trial
研究者
相似试验
已完成
2 期
Phase II study of TS-1+Trastuzumab in HER2-positive advanced gastric cancer patients more than 65 years oldHER2-positive advanced gastric cancerJPRN-UMIN000007368Japna Clinical Cancer Research Organizetion40
招募中
2 期
A phase2 study of trastumab and TS-1 for HER2-positive advanced gastric cancerGastric CancerJPRN-UMIN000006115Shimane University Hospital20
招募中
2 期
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the BreastNode Negative Breast CancerMicrometastasis Breast CancerHormone Receptor Positive Breast CancerBreast CancerNCT04569747Dana-Farber Cancer Institute375
进行中（未招募）
不适用
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study - TRAIN studyHER2 positive breat cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-000987-18-NLetherlands Cancer Institute
已完成
2 期
Combination treatment with TS-1+CDDP+Trastuzumab for unresectable HER 2 positive gastric cancer (A Phase II Study)nresectable HER2 positive gastric cancerJPRN-UMIN000005876Toho University20